-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – LP-184 in Melanoma
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - LP-184 in Melanoma report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. LP-184 in Melanoma Drug Details: LP-184 is under development for the treatment...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – LP-184 in Central Nervous System (CNS) Cancer
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - LP-184 in Central Nervous System (CNS) Cancer report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. LP-184 in Central Nervous System (CNS) Cancer Drug...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – LP-184 in High-Grade Glioma
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - LP-184 in High-Grade Glioma report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. LP-184 in High-Grade Glioma Drug Details: LP-184 is under development for...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – LP-184 in Recurrent Glioblastoma Multiforme (GBM)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - LP-184 in Recurrent Glioblastoma Multiforme (GBM) report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. LP-184 in Recurrent Glioblastoma Multiforme (GBM) Drug Details: LP-184...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – LP-184 in Triple-Negative Breast Cancer (TNBC)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - LP-184 in Triple-Negative Breast Cancer (TNBC) report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. LP-184 in Triple-Negative Breast Cancer (TNBC) Drug Details: LP-184...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – LP-184 in Non-Small Cell Lung Cancer
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - LP-184 in Non-Small Cell Lung Cancer report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. LP-184 in Non-Small Cell Lung Cancer Drug Details: LP-184...
-
Product Insights
NewPediatric Cancer – Drugs In Development, 2024
Empower your strategies with our Pediatric Cancer – Drugs In Development, 2024 report and make more profitable business decisions. Pediatric cancer types include leukemias, brain and other central nervous system (CNS) tumors, and lymphomas. Signs and symptoms include unexplained paleness and loss of energy, easy bruising or bleeding, limping, fever, and headaches. Diagnosis can be done by blood tests, biopsy, ultrasound, MRI, and PET-CT scan. Common treatments include surgery, chemotherapy, radiation therapy, immunotherapy, and stem cell transplant. The Pediatric Cancer drugs...
-
Product Insights
NewAtypical Teratoid Rhabdoid Tumor – Drugs In Development, 2024
Empower your strategies with our Atypical Teratoid Rhabdoid Tumor – Drugs In Development, 2024 report and make more profitable business decisions. Atypical teratoid rhabdoid tumor (ATRT) is a rare and fast-growing cancerous tumor of the brain and spinal cord. About half of these tumors begin in the cerebellum or brain stem. ATRT often appears to result from changes in a gene that normally makes proteins to stop tumor growth. In ATRT, this gene does not function properly, the protein is not...
-
Product Insights
NewMalignant Glioma – Drugs In Development, 2024
Empower your strategies with our Malignant Glioma – Drugs In Development, 2024 report and make more profitable business decisions. Malignant gliomas are aggressive and fast-growing tumors that arise from glial cells in the brain and spinal cord. Gliomas account for the most common type of primary brain tumors in adults. Symptoms of malignant gliomas vary depending on the tumor's size, location, and rate of growth. Common symptoms may include headaches, seizures, cognitive changes, personality or behavior changes, weakness or sensory loss,...
-
Product Insights
NewPediatric Diffuse Intrinsic Pontine Glioma – Drugs In Development, 2024
Empower your strategies with our Pediatric Diffuse Intrinsic Pontine Glioma – Drugs In Development, 2024 report and make more profitable business decisions. Pediatric diffuse intrinsic pontine glioma (DIPG) is a rare and aggressive type of brain tumor that primarily affects children, usually between the ages of five and 10 years. This tumor arises in the brainstem, specifically in the region known as the pons, which controls essential bodily functions such as breathing, heart rate, and muscle control. DIPG tumor location in...